Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study

Dermatol Surg. 2010;36(1):102-8. doi: 10.1111/j.1524-4725.2009.01390.x. Epub 2009 Dec 7.

Abstract

Background: This is the first well-controlled study of the use of botulinum toxin type A (BoNTA) for glabellar lines in China.

Objectives: To evaluate the safety and efficacy of BoNTA in the treatment of glabellar lines in Chinese subjects.

Materials and methods: A total of 227 subjects received a single treatment in a 3:1 randomization ratio of BoNTA (20 U):placebo and were observed for 120 days after injection. Effective outcome measures included investigator's rating of wrinkle severity at maximum frown and rest and subjects' global assessment and self-perception of age.

Results: A significantly higher responder rate at maximum frown, ranging from 94.1% at day 30 to 52.9% at day 120, was noted in the BoNTA group. The proportion of subjects with none or mild glabellar lines at rest was 66.7% in the BoNTA group at day 30. Most (95.3%) of the subjects treated with BoNTA reported better than 50% improvement at day 30, and self-perception of age was less than chronological age. There were no statistically significant differences in adverse events reported between the two groups (p=.06).

Conclusion: A single treatment of 20 U of BoNTA was effective and safe in reducing glabellar lines in Chinese subjects.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Asian People
  • Botulinum Toxins, Type A / administration & dosage*
  • China
  • Double-Blind Method
  • Female
  • Humans
  • Injections, Intramuscular
  • Male
  • Neuromuscular Agents / administration & dosage*
  • Prospective Studies
  • Skin Aging / drug effects*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A